web analytics
10.4 C
Munich
Monday, October 25, 2021

PKG Acquisition; the Bull Run on Cerebain Biotech Corp OTCMKTS: CBBT)

Cerebain Biotech Corp OTCMKTS: CBBT) continues to rocket up the charts in recent days after the Company reported it is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current. CBBT has skyrocketed up off its triple zero lows in August to recent highs of $0.025 per share. Microcapdaily first reported on Cerebain and PKG on October 7 when CBBT was trading at $0.003.

Penny stock speculators are accumulating CBBT as the Company completes its acquisition of PKG, a privately-owned contract manufacturing and engineering company developing high-end medical and aerospace equipment. PKG was doing million in revenues before covid hit and was a major contributor in designing and manufacturing numerous and diverse devices for Fortune 500 companies, mid-size organizations, and start-up businesses. Recently PKG reported their registration with the FDA as an establishment producing medical personal protection equipment (PPE), such as surgical masks. PKG also announced the completion of the transfer of its ISO 13485:2016 and ISO 9001:2015 compliance certificates.

Cerebain Biotech Corp. (OTC: CBBT) is a medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease. The Company is evaluating the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients. Cerebain Biotech says it is in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.

CBBT started running in September after the Company entered into an LOI to purchase the assets of PKG, Inc. (PKG). PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.

To Find out the inside Scoop on CBBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CBBTPKG inc, recently reported an agreement with Adventus Venture, a medical device incubator, to finalize development and manufacturing plans for two companies in their portfolio: Allevion Therapeutics and Pressao Medical. Allevion Therapeutics and Pressao Medical are part of the portfolio of Adventus Ventures, LLC, a medical device venture capital company.

CBBT selected NMS Consulting, Inc; NMS as its strategic advisor to guide it through its planned acquisition of PKG, Inc. As part of the initial scope of services, NMS shall provide management consulting services related to the formal due diligence of the PKG operations and financials in addition to analysis related to revenue and cost synergies/savings, human capital and performance optimization, tax advisory, and mitigation strategy, risk management strategy, transaction and financing structuring to ensure optimal benefits to Cerebain and its shareholders. Additional services shall include post-merger integration, revenue growth strategies, market entry and expansion, digital transformation, cyber-security, and data privacy.

On November 11 CBBT announced in a general business update it is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current. Upon the completion of the acquisition, Cerebain will initiate a review of its overall business and corporate strategic plan. The corporate strategic initiatives to be developed and implemented include rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries.

 

We have a Monster Pick Coming. Subscribe Right Now

Currently running up the charts CBBT is emerging as one of the most exciting stories in small caps quickly attracting legions of new shareholders who continue to bid the stock higher. Cerebain just confirmed it is in the final stages of its acquisition of PKG, Inc., a privately-owned contract manufacturing and engineering company developing high-end medical and aerospace equipment. PKG was doing million in revenues before covid hit and was a major contributor in designing and manufacturing numerous and diverse devices for Fortune 500 companies, mid-size organizations, and start-up businesses. More recently PKG reported their registration with the FDA as an establishment producing medical personal protection equipment (PPE), such as surgical masks. PKG also announced the completion of the transfer of its ISO 13485:2016 and ISO 9001:2015 compliance certificates. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current. CBBT has just 684 Million shares outstanding with OS topped at 1.25 million.We will be updating on CBBT when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBBT.

Disclosure: we hold no position in CBBT either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.